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In his brilliant analysis, Taleb uses the 
phrase ‘black swan’ to designate those 
unusual phenomena that turn out to be 
highly influential and consequential, and 
yet were neither predicted nor antici-
pated.10 Viewed from the clinical and 
environmental perspective of CO as an 
invariant and potentially lethal toxicant, 
it would never have been predicted that, 
in much lower amounts, CO may be a pro-
tectant. Although the challenges in real-
izing the therapeutic potential of CO are 
huge and include the bedeviling truth that, 
in increasing concentrations, CO is trans-
formed from a protectant to a toxicant, 
nonetheless, the prospect that CO affords 
a therapeutic strategy for human disease 
carries, unquestionably, a high impact. CO 
as a therapeutic agent thus appears as a 
black swan. That such an exciting prospect 
exists is an indubitable testament to the 
importance of the initial demonstration 
of the cytoprotective properties of CO, 
the illuminating evidence that followed, 
and the present findings of Nakao et al.1 
demonstrating that CO may assist in pre-
serving the donor kidney.
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Animal models of sepsis  
and its complications
Mitchell P. Fink1,2,3,4
Most currently used animal sepsis models fail to adequately replicate 
the clinical problem and, therefore, have only limited utility for 
investigating pathophysiological mechanisms or testing the efficacy of 
new therapeutic agents. Recent experimental findings support this view 
and suggest that models of acute infection in mice with pre-existing 
renal dysfunction may be useful in the development pathway for new 
therapeutic agents for sepsis.
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Sepsis is a potentially life-threatening 
condition caused by infection and char-
acterized by a poorly controlled systemic 
inflammatory response.1 Severe sepsis is 
sepsis with evidence of acute organ system 
dysfunction, and septic shock is sepsis 
associated with systemic arterial hypo-
tension.1 Sepsis, severe sepsis, and septic 
shock represent a huge public-health prob-
lem; epidemiological data suggest that in 
the United States alone, there are more 
than 600,000 cases annually2,3 and more 
than 200,000 people die every year from 
severe sepsis and its complications.3
Despite the magnitude of the prob-
lem, progress in the development of bet-
ter therapeutic modalities for sepsis has 
been slow. Indeed, only one therapeutic 
agent, drotrecogin alfa (activated), also 
known as recombinant human activated 
protein C, has been shown to improve 
survival in patients with severe sepsis 
and septic shock.4 Although this agent 
has been approved by regulatory agen-
cies in the United States and elsewhere for 
the treatment of selected cases of severe 
sepsis, clinical adoption of recombinant 
human activated protein C has been rela-
tively slow, possibly because of concerns 
about its cost,5 safety,6,7 and/or efficacy.8
Clearly, there remains a need to develop 
improved therapeutic agents to ameliorate 
organ dysfunction and improve survival 
in patients with severe sepsis. Because 
it is enormously expensive to carry out 
clinical trials of new drugs or biologics 
for severe sepsis, only the most promis-
ing agents can be evaluated in this way. 
As a consequence, investigators have 
relied on various animal models of sepsis 
to evaluate the efficacy of various novel 
therapeutic strategies. But animal mod-
els provide, at best, a crude approxima-
tion of human sepsis, especially when one 
considers that outcome in the clinical set-
ting is undoubtedly influenced by myriad 
factors, including genetic background, 
therapeutic interventions and supportive 
care, age, and pre-existing medical condi-
tions. It is noteworthy, therefore, that the 
most commonly studied animal models 
of sepsis use highly inbred strains of mice 
with a consistent genetic background, 
include little or no supportive care as part 
of the protocol, and use young, previously 
healthy subjects.
Probably the most extensively stud-
ied animal models of sepsis use rodents 
(mice or rats) injected with lipopoly-
saccharide (LPS), a compound purified 
from the outer cell wall of Gram-negative 
bacteria. When rodents are injected 
intravenously or intraperitoneally with 
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LPS, a systemic inflammatory response 
is initiated, that bears some resemblance 
to the systemic inflammatory response 
in patients with severe sepsis. For exam-
ple, circulating concentrations of several 
cytokines, such as tumor necrosis factor 
(TNF), interleukin-6, and interleukin-10, 
typically are increased in LPS-challenged 
rodents and septic patients.9 However, 
even in this regard, there are substantial 
differences in the kinetics and magni-
tude of cytokinemia between rodent/LPS 
models and clinical sepsis. Consider just 
one cytokine: TNF. In mice challenged 
with a lethal dose of LPS, circulating 
TNF levels spike rapidly, reaching con-
centrations in the ng/ml range within 
about 60–90 minutes, and then decline 
almost as rapidly, becoming undetect-
able within about 4 hours. In contrast, 
in septic patients, TNF levels typically 
are much lower (the low pg/ml range), 
but supranormal TNF levels persist for 
several days, even among patients with 
an ultimately fatal illness.
Another key difference between the 
rodent/LPS model of sepsis and the clini-
cal syndrome is that, in the former case, the 
inflammatory response is entirely delete-
rious, as there is no infectious focus and 
eradication of pathogenic organisms by the 
host’s immune system is not essential for 
recovery. Thus, effective anti-inflammatory 
agents almost always are protective and 
improve survival and/or organ system func-
tion when administered in a timely fashion 
to mice or rats that have been (or soon will 
be) challenged with LPS. In patients with 
sepsis, while the inflammatory response is 
critical for the pathogenesis of organ sys-
tem (for example, lung, kidney, or liver) 
dysfunction, the inflammatory response 
is also a critical component of the host’s 
defense against the invading microorgan-
isms. Accordingly, in the clinical situation, 
anti-inflammatory therapy is a double-
edged sword, potentially ameliorating 
‘collateral damage’ caused by poorly 
controlled inflammation but also potentially 
compromising the host’s ability to eradi-
cate infection.
In view of these concerns, investiga-
tors have increasingly turned to animal 
models of sepsis that incorporate a true 
focus of infection. The most commonly 
employed such model uses mice that 
have been subjected to cecal ligation 
and puncture (CLP), a procedure that 
induces polymicrobial bacterial perito-
nitis. The CLP model, although far from 
perfect in terms of verisimilitude, clearly 
comes closer to clinical reality than do 
pure inflammation models.
Acute kidney injury (AKI) is a com-
mon clinical problem in intensive care 
unit patients and independently pre-
dicts poor outcome.10 About half of the 
cases of AKI in critically ill intensive 
care unit patients can be attributed to 
sepsis.11 And when the relationship 
between sepsis and AKI is looked at in 
the other direction, the incidence of AKI 
among patients with sepsis ranges from 
about 10% to 50%.12 The mortality rate 
for patients with severe sepsis or septic 
shock and AKI is quite high (~67%), 
and among patients with severe sepsis 
or septic shock, the presence of AKI is 
an independent risk factor for mortality, 
even when other important factors, such 
as severity-of-illness score and age, are 
simultaneously considered.13
For many years, clinicians have recog-
nized that pre-existing renal dysfunction 
is a major risk factor for AKI.14,15 There-
fore, one way that one might increase the 
verisimilitude of a preclinical model of 
sepsis would be to study animals that are 
not perfectly healthy (before the onset of 
infection) but rather are already burdened 
by some degree of pre-existing chronic 
(or at least subacute) renal disease. This is 
precisely the approach investigated by Doi 
et al.16 (this issue). Briefly, these investi-
gators induced a form of subacute renal 
injury in some mice by injecting them 
with a large dose of folic acid (FA). Two 
weeks later, the mice with FA-induced 
renal damage and controls (that is, com-
pletely healthy mice) were subjected to 
CLP to induce bacterial peritonitis. Sep-
sis increased serum creatinine in the FA + 
CLP but not in the Control + CLP group. 
Moreover, compared with the Control + 
CLP group, FA + CLP mice showed bio-
chemical findings indicative of a more 
severe form of sepsis. Not surprisingly, 
mortality over the first 96 hours after the 
induction of peritonitis was significantly 
greater in the FA + CLP group than in 
the Control + CLP group. Thus, pre- 
existing renal injury not only promoted 
the development of sepsis-induced AKI 
but was also associated with development 
of a more lethal form of the syndrome.
Doi and colleagues16 recognized the 
possibility that the administration of FA 
increased susceptibility to bacterial peri-
tonitis via some mechanism unrelated 
to the development of subacute renal 
dysfunction induced by the toxic insult. 
Accordingly, these researchers also inves-
tigated the effects on CLP-induced sepsis 
of pre-existing renal dysfunction initi-
ated in a totally unrelated way (five-sixths 
nephrectomy). The results of these stud-
ies, although more preliminary in nature, 
confirmed the findings obtained with the 
FA-induced renal damage model. These 
data should give investigators in the field 
confidence that the FA + CLP model is 
likely to be a useful one.
The same laboratory that developed 
the FA + CLP paradigm previously used 
a different approach—induction of sep-
sis in aged rather than young mice—in 
an effort to create a model of severe sep-
sis and sepsis-induced AKI that comes 
closer to clinical reality than most prior 
rodent models.17 Both the FA + CLP 
model and the ‘CLP in aged mice’ model 
should provide investigators with valu-
able tools for studying the pathogenesis 
of sepsis (and sepsis-related AKI) or 
investigating new therapeutic agents or 
strategies for the treatment of sepsis and 
sepsis-induced organ dysfunction.
Further verification of the value of 
these models could be obtained by use 
of the models to study a series of agents 
that have been shown in clinical trials to 
be effective or ineffective adjuvant thera-
peutics for severe sepsis. The list of agents 
that have been shown to be effective, 
unfortunately, is very short. It has only 
one entry (recombinant human activated 
protein C), and, as was noted above, the 
effectiveness of this agent remains some-
what controversial. The list of agents that 
have been shown to be ineffective is quite 
long and includes antibodies against TNF, 
interleukin-1 receptor antagonist, various 
platelet-activating factor receptor antag-
onists, ibuprofen, a bradykinin receptor 
antagonist, corticosteroids (controversial), 
and antibodies against LPS. If some or all 
of these ‘failed’ therapeutics also can be 
shown to provide little or no benefit (in 
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terms of organ function or survival) in 
the FA + CLP (or the ‘CLP in aged mice’) 
model (particularly when the test agent is 
administered several hours after the onset 
of sepsis as a so-called ‘rescue’ interven-
tion), then investigators can draw some 
inferences about the negative predictive 
value of these murine sepsis models when 
they are used for evaluating novel drugs or 
biologics as candidates for clinical testing 
in human sepsis.
In accordance with the notion of using 
FA + CLP to evaluate new therapeutic 
strategies, Doi et al.16 used their newly 
developed sepsis model to evaluate two 
novel agents: recombinant human solu-
ble Flt-1 domain D1–3 (Flt-1; a vascu-
lar endothelial growth factor inhibitor) 
and chloroquine, an antimalarial with 
anti-inflammatory activities. Each agent 
alone provided some small benefits, but 
administered together, they significantly 
improved survival and ameliorated AKI. 
The data obtained with the combination 
of Flt-1 and chloroquine are preliminary 
in nature; for example, the agents were 
administered in a preemptive rather than 
a rescue fashion (the latter approach, of 
course, is more clinically relevant). Nev-
ertheless, these results show how the 
FA + CLP model might be used to 
evaluate new therapeutics, and they 
also emphasize that combinations of 
different agents, with non-overlapping 
mechanisms of action, are likely to be 
more successful than monotherapy.
It is inevitable that our advancing 
knowledge of genetics, immunology, 
inflammation biology, endothelial biol-
ogy, and epithelial biology will ultimately 
lead to vastly improved approaches for 
the treatment of sepsis, severe sepsis, 
and septic shock. Translating all this 
new information into better care for 
our patients will be a long, arduous, and 
expensive process. But better, more real-
istic sepsis models can help us to expedite 
this process. Therefore, the current con-
tribution by Doi et al.16 must be regarded 
as a major advance in the field.
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